The prognostic value of long noncoding RNA ZEB1-AS1 on clinical outcomes in human cancer

Wu, Ying; Ding, Ming; Wei, Shuzhen; Wu, Ting; Xu, Rongrong; Zhu, Xiaoli; Liu, Hongbing

doi:10.7150/jca.27263

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2018; 9(20):3690-3698. doi:10.7150/jca.27263 This issue Cite

Research Paper

The prognostic value of long noncoding RNA ZEB1-AS1 on clinical outcomes in human cancer

Ying Wu¹, Ming Ding¹, Shuzhen Wei¹, Ting Wu¹, Rongrong Xu¹, Xiaoli Zhu^1✉, Hongbing Liu^2✉

1. Department of Respiratory Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu 210009, China
2. Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210002 , China

Citation:

Wu Y, Ding M, Wei S, Wu T, Xu R, Zhu X, Liu H. The prognostic value of long noncoding RNA ZEB1-AS1 on clinical outcomes in human cancer. J Cancer 2018; 9(20):3690-3698. doi:10.7150/jca.27263. https://www.jcancer.org/v09p3690.htm

Other styles

Abstract

Background: Although growing evidence have demonstrated that long non-coding RNA ZEB1-AS1 was aberrantly expressed in various types of cancers and can be used as a prognostic marker in cancer, the results remain inconclusive. Therefore, we performed this meta-analysis to evaluate the prognostic value of ZEB1-AS1 in human cancer.

Methods: A literature survey was conducted for all eligible studies by searching the following online databases: PubMed and Embase. The pooled odds ratios (ORs) or hazard ratios (HRs) with a 95 % confidence interval (95 % Cl) were computed to demonstrate its prognostic value.

Results: A total of 14 studies with 1096 individuals were included to evaluate the association of ZEB1-AS1 with clinicopathological features and overall survival (OS). In the pooled analyses stratified by clinicopathological features, ZEB1-AS1 expression was significantly related to depth of tumor (OR=2.92, 95% CI 1.22-7.02), poor histological differentiation (OR=2.72, 95% CI: 1.92-3.86), lymph node metastasis (OR=3.93, 95% CI: 2.65-5.84), distant metastasis (OR=5.34, 95% CI: 2.85-10.02) and tumor stage (OR=2.46, 95% CI 1.42-4.24), but not to tumor size (OR=1.25, 95% CI 0.79-1.96). Altered ZEB1-AS1 expression was found to be an indicator of worse prognosis in OS (HR = 1.94, 95% CI: 1. 66-2.22) among tumor patients.

Conclusions: High ZEB1-AS1expression was associated poor clinical outcome and it can serve as a novel predictive biomarker in various cancers.

Keywords: long non-coding RNA, ZEB1-AS1, prognostic biomarker, cancer

Citation styles

APA

Wu, Y., Ding, M., Wei, S., Wu, T., Xu, R., Zhu, X., Liu, H. (2018). The prognostic value of long noncoding RNA ZEB1-AS1 on clinical outcomes in human cancer. Journal of Cancer, 9(20), 3690-3698. https://doi.org/10.7150/jca.27263.

ACS

Wu, Y.; Ding, M.; Wei, S.; Wu, T.; Xu, R.; Zhu, X.; Liu, H. The prognostic value of long noncoding RNA ZEB1-AS1 on clinical outcomes in human cancer. J. Cancer 2018, 9 (20), 3690-3698. DOI: 10.7150/jca.27263.

NLM

CSE

Wu Y, Ding M, Wei S, Wu T, Xu R, Zhu X, Liu H. 2018. The prognostic value of long noncoding RNA ZEB1-AS1 on clinical outcomes in human cancer. J Cancer. 9(20):3690-3698.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.